Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
13.91
-0.01 (-0.07%)
At close: Aug 5, 2026, 4:00 PM EDT
13.93
+0.02 (0.14%)
After-hours: Aug 5, 2026, 4:15 PM EDT
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Corvus Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $33.14. The average 1-year stock price forecast is 138.25% higher than the current stock price, while the lowest is $27 (+94.10%) and the highest is $42 (+201.94%).
Price Target: $33.14 (+138.25%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jul 1, 2026.
Analyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $27 | Buy | Reiterates | $27 | +94.10% | Jul 1, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Reiterates $30 | Buy | Reiterates | $30 | +115.67% | Jun 12, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $33 | Buy | Reiterates | $33 | +137.24% | May 15, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $40 | Buy | Maintains | $40 | +187.56% | May 15, 2026 |
| Barclays | Barclays | Buy Maintains $28 | Buy | Maintains | $28 | +101.29% | May 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
4.55M
EPS This Year
-0.71
from -0.54
EPS Next Year
-0.97
from -0.71
EPS and Forward PE are based on non-GAAP adjusted numbers.